STAT3 antagonist JSI-124 suppressed both CD11b+Gr-1− e-MDSCs and conventional CD11b+Gr-1+ MDSCs simultaneously and induced considerable recovery of T cell immunity in vivo and in vitro, thereby displaying more significant anti-tumor efficiency than IL-6R Ab. Here, STAT3 is linked to neoplasm.